PFKFB3 and neoplasm: Considering that standard chemotherapy inevitably is associated with the development of chemoresistance, the observation made by Kotowski K. et al. that PFKFB3 inhibition therapy concurs with carboplatin and paclitaxel in therapy-resistant cell lines of gynecological cancers to reduce tumor weight presents an important step in further therapeutic approach (87).